Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment

Remdesivir (RDV) is the onlyUS Food and Drug Administration (FDA)-approved drug for treating COVID-19. However, RDV can only be given by intravenous route, and there is a pressing medical need for oral antivirals. Significant evidence suggests that the role of the parent nucleoside GS-441524 in the clinical outcomes of RDV could be largely underestimated. We performed an in vitro and in vivo drug metabolism and pharmacokinetics (DMPK) assessment to examine the potential of RDV, and particularly GS-441524, as oral drugs. In our in vitro assessments, RDVexhibited prohibitively low stability in human liver microsomes (HLMs, t(1/2) = similar to 1 min), with the primary CYP-mediated metabolism being the mono-oxidation likely on the phosphoramidatemoiety. This observation is poorly alignedwith any potential oral use of RDV, though in the presence of cobicistat, the microsomal stability was drastically boosted to the level observed without enzyme cofactor NADPH. Conversely, GS-441524 showed excellent metabolic stability in human plasma and HLMs. In further in vivo studies in CD-1 mice, GS-441524 displayed a favorable oral bioavailability of 57%. Importantly, GS-441524 produced adequate drug exposure in the mice plasma and lung, and was effectively converted to the active triphosphate, suggesting that it could be a promising oral antiviral drug for treating COVID-19. (C) 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

Automated summary

The study examined the potential of Remdesivir and its parent nucleoside GS-441524 as oral drugs for treating COVID-19. Results showed that Remdesivir had poor stability in vitro, while GS-441524 exhibited better metabolic stability and oral bioavailability, indicating its potential as a promising oral antiviral drug for COVID-19 treatment.